Jonathan Busch Dba Engage Services | |
110 State St Plankinton SD 57368-5736 | |
(605) 682-9258 | |
(605) 734-8113 |
Full Name | Jonathan Busch Dba Engage Services |
---|---|
Speciality | Counselor - Mental Health |
Location | 110 State St, Plankinton, South Dakota |
Authorized Official Name and Position | Jonathan J Busch (OWNER) |
Authorized Official Contact | 6056829258 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Jonathan Busch Dba Engage Services Po Box 65 Plankinton SD 57368-0065 Ph: (605) 682-9258 | Jonathan Busch Dba Engage Services 110 State St Plankinton SD 57368-5736 Ph: (605) 682-9258 |
NPI Number | 1124515218 |
---|---|
Provider Enumeration Date | 04/16/2018 |
Last Update Date | 04/16/2018 |
Identifier | Type | State | Issuer |
---|---|---|---|
1124515218 | NPI | - | NPPES |
2013822 | Medicaid | SD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | 2422 (South Dakota) | Primary |
News Archive
Past studies have shown an association between strict control of blood sugar and increased mortality. These studies have also suggested that a consequence of this strict control is low blood sugar (called hypoglycemia), which may have adverse effects on the heart.
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau' patent family (US Application Serial No. 10/909,125).
Congenital aniridia is a progressive disease that is associated with improper development of eye structures as well as abnormalities in the brain and pancreas. A variety of nonsense mutations in the PAX6 gene are linked with aniridia; however, despite understanding the genetic basis of the disease, few treatment and prevention strategies are available.
Cancer cells may be able to avoid destruction by anti-vascular and anti-angiogenesis agents through a cellular stress response that activates a pro-survival protein called GRP78, according to researchers from the Keck School of Medicine of the University of Southern California.
› Verified 5 days ago